GLPG Galapagos NV

119.21
+2.18  (+2%)
Previous Close 117.03
Open 118.68
Price To Book 4.96
Market Cap 6510629235
Shares 54,614,791
Volume 74,011
Short Ratio
Av. Daily Volume 133,573

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data lower than expectations released June 28, 2018.
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 trial initiation announced July 5, 2017.
Filgotinib
Non-infectious uveitis
Phase 2 enrolment to be completed in 2019.
GLPG1972 - ROCCELLA
Osteoarthritis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2a postive top-line data released November 20, 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 3 trial initiation announced December 17, 2018.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 data due 2Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)
Phase 2 data due 2H 2019.
MOR106 IGUANA
Atopic dermatitis
Phase 2 enrolment to be completed in 2019.
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2 initiation announced January 7, 2019.
GLPG1690 - NOVESA
Systemic sclerosis
Phase 2 initiation announced April 23, 2019.
MOR106 GECKO
Atopic dermatitis

Latest News

  1. What Kind Of Shareholder Appears On The Galapagos NV's (AMS:GLPG) Shareholder Register?
  2. Better Buy: Vertex Pharmaceuticals vs. Galapagos
  3. Will Gilead Stock Get A Needed Boost From This Week’s Earnings Report?
  4. Galapagos NV (GLPG) Q1 2019 Earnings Call Transcript
  5. Galapagos reports on historic first quarter 2019
  6. Here is What Hedge Funds Really Think About Galapagos NV (GLPG)
  7. Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
  8. Galapagos creates new warrant plans
  9. Gilead stock upgraded to buy from neutral at UBS
  10. Why Galapagos NV Stock Bolted Higher in March
  11. Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
  12. Publication of the annual report and invitation to the annual shareholders' meeting
  13. Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why
  14. Why Galapagos Stock Is Crushing It Today
  15. Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint
  16. Gilead Sciences and Galapagos Stock Are Rising on Upbeat Trial Data
  17. The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead
  18. GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
  19. Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
  20. Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study